Elite Pharmaceuticals
Specialty pharmaceutical company developing abuse deterrent opioids and niche generics to curb misuse and abuse.
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 138 % | 41 % | 27 % | 6 % | 66 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (105 %) | (4 %) | 14 % | 20 % | 16 % | 12 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (123 %) | (12 %) | 20 % | 28 % | 10 % | 36 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 31 % | 20 % | 13 % | 18 % | 12 % |
Source: Company filings or news article
Related Content
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing niche generic drugs and abuse deterrent opioid products. The company operates in the pharmaceutical industry, targeting both healthcare providers and patients who require effective pain management solutions. Elite's business model revolves around leveraging its proprietary pharmacological abuse deterrent technology to create opioid products that are less prone to misuse and abuse. This technology can be applied to all opioids, making it a versatile solution in the fight against opioid addiction. The company generates revenue through the sale of its generic and abuse deterrent products, primarily to healthcare institutions and pharmacies. Elite's market includes both the generic drug sector and the specialized segment for abuse deterrent formulations, addressing a critical need in the healthcare system. By focusing on oral sustained and controlled release drug products, Elite aims to provide safer and more effective treatment options for patients.
Keywords: abuse deterrent opioids, niche generics, pharmacological technology, opioid misuse prevention, healthcare providers, pain management, oral sustained release, controlled release drugs, pharmaceutical industry, drug development.